Article Archive: Damien Conover, CFA

Title Collection Author Date
Why We Like Eli Lilly Today US Videos Damien Conover, CFA 10/11/17
Pfizer's Divestiture Plan No Big Deal Stock Analyst Update Damien Conover, CFA 10/10/17
Healthcare: Stock Selection Key as Valuations Rise Quarter-End Insights Damien Conover, CFA 09/28/17
Pfizer Looks Undervalued Stock Analyst Update Damien Conover, CFA 08/01/17
Pfizer Remains Underappreciated US Videos Damien Conover, CFA 08/01/17
Lilly Looks Slightly Undervalued Stock Analyst Update Damien Conover, CFA 07/25/17
Japan's Approval of Olumiant Good News for Lilly Stock Analyst Update Damien Conover, CFA 07/03/17
Healthcare: ACA Repeal Efforts Unlikely to Yield Major Legislative Changes Quarter-End Insights Damien Conover, CFA 06/28/17
Our Top 2 Picks Within Immuno-Oncology US Videos Damien Conover, CFA 06/07/17
Undervalued Pfizer Offers Great Dividend Opportunity US Videos Damien Conover, CFA 06/06/17
Solid Pipeline Offsets Competition for AstraZeneca Stock Analyst Update Damien Conover, CFA 05/12/17
Merck Posts Minor Gains in First Quarter Stock Analyst Update Damien Conover, CFA 05/02/17
Patent Losses, Prevnar Weakness Weigh on Pfizer Growth Stock Analyst Update Damien Conover, CFA 05/02/17
AbbVie Posts Solid First Quarter Boosted by Humira Stock Analyst Update Damien Conover, CFA 04/27/17
Valuation Concerns at J&J Stock Analyst Update Damien Conover, CFA 04/18/17
Healthcare: Stock-Picking Increasingly Important as Valuations Rise Quarter-End Insights Damien Conover, CFA 03/31/17
Drug Launches, Diversity Support Bayer's Steady Gains Stock Strategist Damien Conover, CFA 03/29/17
3 Drugmakers With Strong Pricing Power US Videos Damien Conover, CFA 03/15/17
Keytruda Helps Offset Generic Headwinds for Merck Stock Analyst Update Damien Conover, CFA 02/02/17
Pfizer Shares Look Undervalued Stock Analyst Update Damien Conover, CFA 01/31/17
AbbVie Looks Undervalued Stock Strategist Damien Conover, CFA 01/30/17
J&J Shares Fairly Valued After Mixed Fourth Quarter Stock Analyst Update Damien Conover, CFA 01/24/17
Healthcare: What Does a Trump Administration Mean for Healthcare Stocks? Quarter-End Insights Damien Conover, CFA 12/29/16
2 Inexpensive, Innovative Pharma Stocks US Videos Damien Conover, CFA 12/05/16
U.S. Elections Add Uncertainty to Healthcare Stocks Stock Analyst Update Damien Conover, CFA 11/09/16
Pfizer Looks Undervalued Despite Pipeline Setback Stock Analyst Update Damien Conover, CFA 10/31/16
Weak Third Quarter but Eli Lilly Looks Well Positioned Stock Analyst Update Damien Conover, CFA 10/25/16
Merck Posts Solid Third Quarter Stock Analyst Update Damien Conover, CFA 10/25/16
Competition Is Concerning for Johnson & Johnson Stock Analyst Update Damien Conover, CFA 10/18/16
Bristol-Myers Squibb's Lost Ground Stock Analyst Update Damien Conover, CFA 10/10/16
Healthcare: We See Value in the Drug and Biotech Industries Quarter-End Insights Damien Conover, CFA 10/05/16
Drug Pricing Power Transcends Politics Stock Strategist Damien Conover, CFA 09/09/16
Clinton Drug Plan No Threat to Innovators Stock Analyst Update Damien Conover, CFA 09/02/16
Pfizer Expands Cancer Platform With High-Priced Medivation Acquisition Commentary Damien Conover, CFA 08/22/16
No Pain, Potential for Lots of Gain Stock Strategist Industry Reports Damien Conover, CFA 08/19/16
Merck Could Gain from Bristol's Poor Drug Trial Results Stock Analyst Update Damien Conover, CFA 08/05/16
Lilly's Growth Prospects Are Improving Stock Strategist Damien Conover, CFA 08/01/16
Where Pharma Firms Still Have Pricing Power US Videos Damien Conover, CFA 08/01/16
What the Market Misses About Eli Lilly US Videos Damien Conover, CFA 07/27/16
Drug Group Lifts J&J; Shares Still Overvalued Commentary Damien Conover, CFA 07/19/16
Healthcare: Stock Selection Increasingly Important Quarter-End Insights Damien Conover, CFA 06/30/16
Recent Drug Launches Buoy Bayer's Growth Stock Strategist Damien Conover, CFA 04/27/16
Steady Growth at J&J Reinforces Wide Moat, But Shares Overpriced Commentary Damien Conover, CFA 04/19/16
Allergan Still Undervalued as Likelihood of Pfizer Deal Fades Commentary Damien Conover, CFA 04/05/16
Healthcare: Drug Reform Worries Are Overblown Stock Strategist Damien Conover, CFA 03/29/16
Healthcare Slump Is a Buying Opportunity US Videos Damien Conover, CFA 02/17/16
Pfizer's Pipeline Productivity Is Improving Stock Strategist Damien Conover, CFA 02/05/16
Pfizer Looks Undervalued Commentary Damien Conover, CFA 02/02/16
Steady Growth Supports J&J’s Wide Moat Commentary Damien Conover, CFA 01/26/16
Healthcare: Even After Uptick, Some Great Values Remain Quarter-End Insights Damien Conover, CFA 12/30/15